Stock Analysis
ResMed Inc. (RMD) Stock Analysis
ResMed Inc. (RMD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
ResMed Inc. (RMD) currently has an AIQ Score of 68/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RMD at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $229.94 |
| AIQ Score | 68/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $33.56B |
| P/E Ratio (TTM) | 22.16 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $2.65 |
| Revenue (quarter ended 2026-06-30) | $1.46B |
| Dividend Yield (TTM) | 1.06% |
| Beta | 0.75 |
| Volume | 3.47M |
| 52-week range | $180.27-$277.67 |
| RSI 14 | 81.85 |
| 50-Day SMA | $231.77 |
| 200-Day SMA | $225.03 |
| Analyst Price Target | $245.93 |
| Next Earnings | Jan 28, 2027 |
RMDResMed Inc.
Healthcare / Medical - Instruments & Supplies
Leader
Sector Leader
Latest quote
- Momentum82
- Value42
- Quality80
- Risk resilience76
- Sentiment—
RMD Stock Analysis Summary
ResMed Inc. (RMD) currently has an AIQ Score of 68/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RMD has AIQ Score of 68/100 with Momentum base of 82/100 and fading Value at 42/100. Wait for component alignment before adding exposure.
Momentum (82/100) leads while Value (42/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -9.05% stock move · RMD classified in Medical - Instruments & Supplies.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RMD Bullish or Bearish Right Now?
RMD currently has a neutral overall setup. Momentum is the strongest factor at 82/100, while Value is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 80/100.
- - Momentum is constructive at 82/100.
- - Risk Resilience is supportive at 76/100.
- - Price is +9.09% above its 50-day SMA.
- - Analyst target implies +6.95% upside from the latest quote.
- - Value is the current constraint at 42/100.
Current Consensus
RMD's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 4 neutral, and 4 sell votes. RMD's 14-day RSI is 81.85, which places the stock in an overbought momentum range. RMD's beta is 0.75, indicating lower market sensitivity than the broad market.
What Changed in RMD?
The largest recent change in RMD is Momentum moving down by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the RMD Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RMD Decision Framework
Public evidence layers, setup checks, and risk context for ResMed Inc..
ResMed Inc. (RMD) Stock Analysis
ResMed Inc. has an AIQ Score of 68/100 in a Neutral regime. Momentum is strongest at 82/100. Beta is 0.75, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RMD is in a Neutral AIQ regime with score 68/100. |
| Signal Conflict | The primary conflict is that momentum leads at 82/100 while value lags at 42/100. |
| Factor Evidence | Momentum 82/100 · Value 42/100 · Quality 80/100 · Risk 76/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 82/100.
Momentum is 82/100 and RSI (14) is 81.9.
RMD is in a Neutral regime at 68/100.
Risk factor is 76/100 with beta 0.75 and annual volatility 28.8%.
Current conflict: momentum leads at 82/100 while value lags at 42/100.
RMD Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RMD Fundamentals
RMD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RMD Technical Analysis
RMD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RMD Stock Catalysts
Track RMD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RMD Dividend Analysis
RMD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RMD Financial Data
RMD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RMD Risk Analysis
RMD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RMD Stock News
RMD stock news, market tone, recent headlines, and catalyst context.
RMD vs Medical Devices Peers
Current peer cohort: RMD · SOLV · STE · SYK · TFX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RMD Current stock | 68/100 | 42/100 | 82/100 | 76/100 | 0 | 28.80% | Current |
| SOLV Solventum | 58/100 | 67/100 | 38/100 | 54/100 | 0.62 | 29.98% | RMD vs SOLV |
| STE Steris | 63/100 | 48/100 | 83/100 | 71/100 | -0.1 | 26.00% | RMD vs STE |
| SYK Stryker | 62/100 | 42/100 | 80/100 | 64/100 | -0.54 | 30.40% | RMD vs SYK |
| TFX Teleflex | 61/100 | 61/100 | 84/100 | 67/100 | 0.35 | 39.71% | RMD vs TFX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RMD
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RMD
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RMD Stock FAQ
What is RMD stock price today?
ResMed Inc.'s current stock price is $229.94. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RMD bullish or bearish right now?
RMD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RMD's market cap?
RMD's market cap is $33.56B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RMD's current P/E ratio?
RMD's current P/E ratio is 22.16 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RMD's RSI?
RMD's 14-day RSI is 81.85 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RMD above its 50-day and 200-day moving averages?
RMD is 9.09% from its 50-day SMA and 12.35% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RMD's next earnings date?
RMD's next earnings date is currently listed as Jan 28, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RMD pay a dividend?
RMD's dividend yield is 1.06% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.